These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29637509)

  • 1. Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.
    Coleman N; Michalarea V; Alken S; Rihawi K; Lopez RP; Tunariu N; Petruckevitch A; Molife LR; Banerji U; De Bono JS; Welsh L; Saran F; Lopez J
    J Neurooncol; 2018 Aug; 139(1):107-116. PubMed ID: 29637509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
    Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
    Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
    Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
    Mantica M; Pritchard A; Lieberman F; Drappatz J
    J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
    Lamborn KR; Yung WK; Chang SM; Wen PY; Cloughesy TF; DeAngelis LM; Robins HI; Lieberman FS; Fine HA; Fink KL; Junck L; Abrey L; Gilbert MR; Mehta M; Kuhn JG; Aldape KD; Hibberts J; Peterson PM; Prados MD;
    Neuro Oncol; 2008 Apr; 10(2):162-70. PubMed ID: 18356283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years.
    Niu X; Wang T; Zhou X; Yang Y; Wang X; Zhang H; Chen N; Yue Q; Wang F; Zhang Y; Liu Y; Mao Q
    J Neurooncol; 2020 Apr; 147(2):377-386. PubMed ID: 32157551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
    Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
    Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients.
    Jones RL; Olmos D; Thway K; Fisher C; Tunariu N; Postel-Vinay S; Scurr M; de Bono J; Kaye SB; Judson IR
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):423-9. PubMed ID: 21069341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
    Sundar R; McVeigh T; Dolling D; Petruckevitch A; Diamantis N; Ang JE; Chenard-Poiriér M; Collins D; Lim J; Ameratunga M; Khan K; Kaye SB; Banerji U; Lopez J; George AJ; de Bono JS; van der Graaf WT
    Eur J Cancer; 2018 Sep; 101():55-61. PubMed ID: 30025230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etiology and prognosis of acute respiratory failure in patients with primary malignant brain tumors admitted to the intensive care unit.
    Decavèle M; Rivals I; Marois C; Cantier M; Weiss N; Lemasle L; Prodanovic H; Hoang-Xuan K; Idbaih A; Similowski T; Demoule A
    J Neurooncol; 2019 Mar; 142(1):139-148. PubMed ID: 30536197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
    Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P
    Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
    Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
    Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.
    Gounder MM; Nayak L; Sahebjam S; Muzikansky A; Sanchez AJ; Desideri S; Ye X; Ivy SP; Nabors LB; Prados M; Grossman S; DeAngelis LM; Wen PY
    J Clin Oncol; 2015 Oct; 33(28):3186-92. PubMed ID: 26282642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.